Inactive Instrument

Press Releases CinCor Pharma, Inc.

Equities

CINC

US17240Y1091

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Acquisition of CinCor Pharma complete	23-02-27	AQ
CinCor Pharma : Acquisition/Asset Disposal - Form 8-K	23-02-24	PU
CINCOR PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-02-24	AQ
CINCOR PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-02-21	AQ
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat	23-02-21	GL
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat	23-02-21	AQ
CINCOR PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC	23-01-24	BU
CINCOR PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC	23-01-10	BU
Astrazeneca strikes $1.8bn deal for Cincor	23-01-10	AQ
CINCOR PHARMA, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	23-01-09	AQ
CinCor Pharma to be Acquired by AstraZeneca	23-01-09	GL
CinCor Pharma to be Acquired by AstraZeneca	23-01-09	AQ
CinCor Pharma : HALO Program Update Presentation	22-11-28	PU
CINCOR PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-11-28	AQ
CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension	22-11-28	AQ
CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences	22-11-22	AQ
CinCor Pharma to Present at Upcoming Jefferies London Healthcare Conference	22-11-09	AQ
CINCOR PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-11-08	AQ
CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions	22-11-07	AQ
CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant Hypertension	22-11-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CinCor Pharma, Inc.

Equities

CINC

US17240Y1091

Press Releases

Filters